Structure-guided development of heterodimer-selective GPCR ligands

Nature Communications

Volumn 7, Issue , 2016, Pages

  Hubner, Harald ^a   Schellhorn, Tamara ^a   Gienger, Marie ^a   Schaab, Carolin ^a   Kaindl, Jonas ^a   Leeb, Laurin ^a   Clark, Timothy ^a,b   Moller, Dorothee ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; CYCLIC AMP; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; HETERODIMER; LIGAND; MACROGOL; NEUROTENSIN 1 RECEPTOR; NEUROTENSIN RECEPTOR; QUINPIROLE; SPIPERONE; UNCLASSIFIED DRUG;

CELLS AND CELL COMPONENTS; CRYSTAL STRUCTURE; LIGAND; POLYMER; PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL LINE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; PHARMACOPHORE; PROTEIN EXPRESSION; PROTEIN FUNCTION; BINDING COMPETITION; CHEMISTRY; HEK293 CELL LINE; METABOLISM; PROTEIN MULTIMERIZATION; STRUCTURE ACTIVITY RELATION;

BINDING, COMPETITIVE; CYCLIC AMP; HEK293 CELLS; HUMANS; LIGANDS; PROTEIN MULTIMERIZATION; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84979787994     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12298     Document Type: Article

References (55)

1. Kobilka, B. K. G protein coupled receptor structure and activation. Biochim. Biophys. Acta 1768, 794-807 (2007).
2. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2, 274-286 (2001).
3. Ferre, S., Ciruela, F., Woods, A. S., Lluis, C., Franco, R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci. 30, 440-446 (2007).
4. George, S. R., O'Dowd, B. F., Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov. 1, 808-820 (2002).
5. Han, Y., Moreira, I. S., Urizar, E., Weinstein, H., Javitch, J. A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 5, 688-695 (2009).
6. Bellot, M. et al. Dual agonist occupancy of AT1-R-alpha2C-AR heterodimers results in atypical Gs-PKA signaling. Nat. Chem. Biol. 11, 271-279 (2015).
7. Milligan, G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14 (2009).
8. Guo, W. et al. Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J. 27, 2293-2304 (2008).
9. Albizu, L. et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6, 587-594 (2010).
10. Scarselli, M. et al. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276, 30308-30314 (2001).
11. Lee, S. Oligomerization of dopamine and serotonin receptors. Neuropsychopharmacology. 23, S32-S40 (2000).
12. Hillion, J. et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 277, 18091-18097 (2002).
13. Urizar, E. et al. CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat. Chem. Biol. 7, 624-630 (2011).
14. Hasbi, A. et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc. Natl Acad. Sci. USA 106, 21377-21382 (2009).
15. Wang, M. et al. Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. Mol. Brain 3, 25 (2010).
16. Bagalkot, T. R. et al. Chronic social defeat stress increases dopamine D2 receptor dimerization in the prefrontal cortex of adult mice. Neuroscience 311, 444-452 (2015).
17. Binder, E. B., Kinkead, B., Owens, M. J., Nemeroff, C. B. Neurotensin and dopamine interactions. Pharmacol. Rev. 53, 453-486 (2001).
18. Boules, M., Fredrickson, P., Muehlmann, A., Richelson, E. Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders. Behav. Sci. 4, 125-153 (2014).
19. Fuxe, K. et al. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann. NY Acad. Sci. 668, 186-204 (1992).
20. Koschatzky, S., Tschammer, N., Gmeiner, P. Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics. ACS Chem. Neurosci. 2, 308-316 (2011).
21. Borroto-Escuela, D. O. et al. Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochem. Biophys. Res. Commun. 435, 140-146 (2013).
22. Kinkead, B., Binder, E. B., Nemeroff, C. B. Does neurotensin mediate the effects of antipsychotic drugs? Biol. Psychiatry 46, 340-351 (1999).
23. Hiller, C., Kühhorn, J., Gmeiner, P., Class, A. G-protein-coupled receptor (GPCR) dimers and bivalent ligands. J. Med. Chem. 56, 6542-6559 (2013).
24. Shonberg, J., Scammells, P. J., Capuano, B. Design strategies for bivalent ligands targeting GPCRs. ChemMedChem. 6, 963-974 (2011).
25. Waldhoer, M. et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl Acad. Sci. USA 102, 9050-9055 (2005).
26. Daniels, D. J. et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl Acad. Sci. USA 102, 19208-19213 (2005).
27. Akgün, E. et al. Inhibition of inflammatory and neuropathic pain by targeting a Mu opioid receptor/chemokine Receptor5 heteromer (MOR-CCR5). J. Med. Chem. 58, 8647-8657 (2015).
28. McRobb, F. M., Crosby, I. T., Yuriev, E., Lane, J. R., Capuano, B. Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation. J. Med. Chem. 55, 1622-1634 (2012).
29. Butini, S. et al. Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors. J. Med. Chem. 53, 4803-4807 (2010).
30. Gogoi, S. et al. Novel bivalent ligands for D2/D3 dopamine receptors: significant cooperative gain in D2 affinity and potency. ACS Med. Chem. Lett. 3, 991-996 (2012).
31. Soriano, A. et al. Adenosine A2A receptor-antagonist/dopamine D2 receptoragonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med. Chem. 52, 5590-5602 (2009).
32. Kühhorn, J. et al. Development of a bivalent dopamine D(2) receptor agonist. J. Med. Chem. 54, 7911-7919 (2011).
33. Jacobson, K. A., Xie, R., Young, L., Chang, L., Liang, B. T. A novel pharmacological approach to treating cardiac ischemia: binary conjugates of A1 and A3 adenosine receptor agonists. J. Biol. Chem. 275, 30272-30279 (2000).
34. Tschammer, N. et al. Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D-3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. J. Med. Chem. 54, 2477-2491 (2011).
35. Dörfler, M., Tschammer, N., Hamperl, K., Hübner, H., Gmeiner, P. Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J. Med. Chem. 51, 6829-6838 (2008).
36. Chien, E. Y. et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095 (2010).
37. Löber, S., Hübner, H., Tschammer, N., Gmeiner, P. Recent advances in the search for D3-and D4-selective drugs: probes, models and candidates. Trends Pharmacol. Sci. 32, 148-157 (2011).
38. White, J. F. et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513 (2012).
39. Egloff, P. et al. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli. Proc. Natl Acad. Sci. USA 111, E655-E662 (2014).
40. Hiller, C. et al. Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. J. Med. Chem. 56, 5130-5141 (2013).
41. Huang, J., Chen, S., Zhang, J. J., Huang, X.-Y. Crystal structure of oligomeric b1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat. Struct. Mol. Biol. 20, 419-425 (2013).
42. Einsiedel, J. et al. Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics. J. Med. Chem. 54, 2915-2923 (2011).
43. Jiang, L. I. et al. Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J. Biol. Chem. 282, 10576-10584 (2007).
44. Peterson, S. M. et al. Elucidation of G-protein and b-arrestin functional selectivity at the dopamine D2 receptor. Proc. Natl Acad. Sci. USA 112, 7097-7102 (2015).
45. Neve, K. A., Cox, B. A., Henningsen, R. A., Spanoyannis, A., Neve, R. L. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol. Pharmacol. 39, 733-739 (1991).
46. Lefkowitz, R. J. A brief history of G protein-coupled receptors (Nobel Lecture). Angew Chem. Int. Ed. Engl. 52, 6366-6378 (2013).
47. Hollenberg, M. D. et al. Derivatized 2-furoyl-LIGRLO-amide, a versatile and selective probe for proteinase-activated receptor 2: binding and visualization J. Pharmacol. Exp. Ther. 326, 453-462 (2008).
48. Shoichet, B. K., Kobilka, B. K. Structure-based drug screening for G-proteincoupled receptors. Trends Pharmacol. Sci. 33, 268-272 (2012).
49. Trott, O., Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).
50. Hornak, V. et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725 (2006).
51. Jojart, B., Martinek, T. A. Performance of the general amber force field in modeling aqueous POPC membrane bilayers. J. Comput. Chem. 28, 2051-2058 (2007).
52. Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
53. Hübner, H., Haubmann, C., Utz, W., Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments and computational studies of novel dopamine receptor agonists recognizing preferentially the D3 subtype. J. Med. Chem. 43, 756-762 (2000).
54. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
55. Cheng, Y.-C., Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).